Unveiling the roles of HBV polymerase for new antiviral strategies

Daniel N. Clark, Jianming Hu

Research output: Contribution to journalReview articlepeer-review

34 Scopus citations


Infection with HBV is common worldwide, with over 350 million chronic carriers. Chronic HBV infection is associated with cirrhosis and hepatocellular carcinoma. All currently available oral antivirals are directed against the HBV polymerase enzyme, a reverse transcriptase. HBV polymerase contains several important domains and motifs which define its functions and reveal ways to further target it. This enzyme executes many functions required for the HBV replication cycle, including viral RNA binding, RNA packaging, protein priming, template switching, DNA synthesis and RNA degradation. In addition, HBV polymerase must interact with host proteins for its functions. Future therapeutics may inhibit not only the DNA synthesis steps which are carried out by the reverse transcriptase domain (as all current antivirals do) but other domains, functions and interactions which are essential to the HBV replication cycle.

Original languageEnglish (US)
Pages (from-to)283-295
Number of pages13
JournalFuture Virology
Issue number3
StatePublished - Mar 1 2015

All Science Journal Classification (ASJC) codes

  • Virology


Dive into the research topics of 'Unveiling the roles of HBV polymerase for new antiviral strategies'. Together they form a unique fingerprint.

Cite this